GlassScriptPhysician profile
Andrew R Chema
NPI 1053572560
$3,550.03
in general payments reported to CMS, 2019-2025
37 companies · $426 in 2025
The $426 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $908 · 2020: $344 · 2022: $121 · 2023: $1,199 · 2024: $553 · 2025: $426.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,177.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,177.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $900.09 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Pfizer INC. | $397.44 | 2019-2025 | |
| Novo Nordisk INC | $283.60 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $258.32 | 2019-2024 | Mounjaro, Zepbound |
| Merck Sharp & Dohme LLC | $205.31 | 2019-2023 | Verquvo, Steglatro, Belsomra |
| Glaxosmithkline, LLC. | $196.38 | 2019-2024 | Trelegy Ellipta |
| Daiichi Sankyo INC. | $156.10 | 2023-2025 | Injectafer |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $131.39 | 2022-2025 | Xifaxan, Trulance |
| Amgen INC. | $107.63 | 2019-2025 | Krystexxa, Repatha, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $74.64 | 2019-2024 | Ofev |
| Novartis Pharmaceuticals Corporation | $62.06 | 2022-2024 | |
| E.R. Squibb & Sons, L.L.C. | $58.82 | 2019-2024 | Camzyos, Eliquis |
| Takeda Pharmaceuticals U.S.A., INC. | $55.49 | 2019 | |
| Astellas Pharma US INC | $54.55 | 2023-2024 | Veozah, Myrbetriq |
| Abbott Laboratories | $45.78 | 2025 | Eterna, Freestyle Libre 2 |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Chema listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.